Health product safety alerts
Safety alerts and advisories from Canada and other countries all in one place.
Countries
⇡ Canada
Health Canada – Find recalls, advisories and safety alerts
⇡ United States
⇡ France
⇡ UK
- Healthcare professionals prescribing dupilumab should be alert to the risks of ocular reactions. New onset or worsening ocular symptoms require prompt review. Referral for ophthalmological examination should be made as appro…
- The MHRA is reviewing its approach to engaging with healthcare professionals on the safety of medicines and medical devices. Through our consultation, you can provide your views and help inform our new approach.
- Recent information relating to COVID-19 vaccines and medicines that has been published since the October 2022 issue of Drug Safety Update, up to 24 November 2022.
- A summary of recent letters and notifications sent to healthcare professionals about medicines.
- The seventh annual #MedSafetyWeek social media campaign will take place 7 to 13 November 2022 and this year’s focus is the importance of reporting suspected adverse reactions to medicines and vaccines. We are also encouragin…
- Recent information relating to COVID-19 vaccines and medicines that has been published since the September 2022 issue of Drug Safety Update, up to 21 October 2022.
- A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
- Prescribers and dispensers should use caution if switching patients between different long-acting formulations of methylphenidate (Concerta XL, Medikinet XL, Equasym XL, Ritalin LA, and generics) as different instructions fo…
- The third-line treatment indication for rucaparib has been withdrawn following a review of the findings of the ARIEL-4 trial, which showed lower overall survival for rucaparib treatment versus standard chemotherapy in patien…
- Recent information relating to COVID-19 vaccines and medicines that has been published since the August 2022 issue of Drug Safety Update, up to 23 September 2022.
⇡ New Zealand
- Goserelin (Teva) 3.6mg and 10.8 mg implants and reports of issues when administering this medicine
- Myocarditis and pericarditis have been reported with Nuvaxovid (Novavax COVID-19 Vaccine)
- Recall of KetoSens Test Strips – batch UJ03PBXNG
- Update – Possible risk of vasculitis with vildagliptin products (Galvus, Galvumet)
- Abnormal uterine bleeding and oral anticoagulants (blood thinners)
- Medsafe is publishing a warning that the product Nhan Sam Tuyet Lien Truy Phong Hoan should not be consumed
- Accuretic found to contain nitrosamines
- Typographical error in Healgen Rapid COVID-19 Antigen Self-Test (RATs) patient instruction leaflet
- Reminder: Miracle Mineral Solution has dangerous and potentially life-threatening side effects
- Possible risk of vasculitis with vildagliptin products (Galvus, Galvumet)
Pharmacy Space 